Article
Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.